News Headlines

  1. Wheeler Bio And Pharmefex Consulting Announce Strategic Partnership To Integrate IND Drafting And CMC Support Into Wheeler's ModularCMC™ Platform 9/9/2025

    Wheeler Bio, Inc., a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has established a strategic partnership with Pharmefex Consulting, an expert CMC consultancy with deep expertise in regulatory strategy and technical operations, focused on accelerating client success in Investigational New Drug (IND) filings and regulatory submissions.

  2. Kenox Enters Into Strategic Product Development Partnership With Strides 9/9/2025

    Strides Pharma Science Ltd today announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).

  3. Almac Group Expands Bioavailability Enhancement Capabilities – Addressing A Critical Need In Drug Development 9/9/2025

    Almac Group has completed a multi-million-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK.

  4. Evonik And Ethris Enter Strategic Partnership To Expand Offerings For Nucleic Acid Delivery 9/9/2025

    Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery.

  5. ScaleReady Awards G-Rex® Grants To Support Cell And Gene Therapy Manufacturing In California 9/9/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program.

  6. KBI Biopharma, Inc. Announces Collaboration With Infinimmune Inc. To Support Antibody Manufacturing 9/8/2025

    KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.

  7. Matica Biotechnology And Cirsium Biosciences Announce AAV Manufacturing Collaboration 9/8/2025

    Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, and Cirsium Biosciences ("Cirsium"), a biotechnology company developing a breakthrough plant-based AAV (adeno-associated virus) technology, today announced a non-exclusive strategic partnership.

  8. Made Scientific And Hemogenyx Pharmaceuticals Announce Technology Transfer And Manufacturing Partnership To Advance HG-CT-1, An Autologous CAR-T Cell Therapy For Acute Myeloid Leukemia 9/8/2025

    Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases, today announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.

  9. New Hopewell NJ Facility Showcases Enzene's Continuous Manufacturing Platform 9/4/2025

    Governor Phil Murphy officially inaugurated the state-of-the-art biomanufacturing facility of Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), marking a significant milestone in the expansion of global biotech capabilities in the United States.

  10. Zydus And Synthon Entered Into Exclusive Licensing And Supply Agreement For Ozanimod Capsules (Generic Version Of ZEPOSIA®) For The U.S. Market 9/4/2025

    Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.